These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 25017425)

  • 1. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study).
    King HL; Keller SB; Giancola MA; Rodriguez DA; Chau JJ; Young JA; Little SJ; Smith DM
    AIDS Behav; 2014 Sep; 18(9):1722-5. PubMed ID: 25017425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco.
    Gilmore HJ; Liu A; Koester KA; Amico KR; McMahan V; Goicochea P; Vargas L; Lubensky D; Buchbinder S; Grant R
    AIDS Patient Care STDS; 2013 Oct; 27(10):560-6. PubMed ID: 24093809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis.
    Keller SB; Smith DM
    AIDS; 2011 Nov; 25(18):2308-10. PubMed ID: 22067201
    [No Abstract]   [Full Text] [Related]  

  • 4. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
    Solomon MM; Mayer KH; Glidden DV; Liu AY; McMahan VM; Guanira JV; Chariyalertsak S; Fernandez T; Grant RM;
    Clin Infect Dis; 2014 Oct; 59(7):1020-6. PubMed ID: 24928295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.
    Cohen SE; Vittinghoff E; Bacon O; Doblecki-Lewis S; Postle BS; Feaster DJ; Matheson T; Trainor N; Blue RW; Estrada Y; Coleman ME; Elion R; Castro JG; Chege W; Philip SS; Buchbinder S; Kolber MA; Liu AY
    J Acquir Immune Defic Syndr; 2015 Apr; 68(4):439-48. PubMed ID: 25501614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Jan; 60(3):65-8. PubMed ID: 21270743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.
    Li J; Dufrene SL; Okulicz JF
    Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV preexposure prophylaxis: new data and potential use.
    Celum CL
    Top Antivir Med; 2011 Dec; 19(5):181-5. PubMed ID: 22298887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men.
    Marcus JL; Glidden DV; McMahan V; Lama JR; Mayer KH; Liu AY; Montoya-Herrera O; Casapia M; Hoagland B; Grant RM
    PLoS One; 2014; 9(3):e91513. PubMed ID: 24637511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men.
    Dolling D; Phillips AN; Delpech V; Pillay D; Cane PA; Crook AM; Shepherd J; Fearnhill E; Hill T; Dunn D; ;
    HIV Med; 2012 May; 13(5):309-14. PubMed ID: 22151684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
    Lorente N; Fugon L; Carrieri MP; Andreo C; Le Gall JM; Cook E; Aboulker JP; Capitant C; Molina JM; Spire B
    AIDS Care; 2012; 24(4):468-77. PubMed ID: 22085083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pre-exposure prophylaxis for the prevention of sexual HIV transmission; new preventative strategy using tenofovir/emtricitabine].
    Boot J; Rump BO; Boucher CA; Op de Coul EL; van Agtmael MA; van de Vijver DA; Burger DM; Fanoy EB
    Ned Tijdschr Geneeskd; 2013; 157(27):A6063. PubMed ID: 23838402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.
    Mutua G; Sanders E; Mugo P; Anzala O; Haberer JE; Bangsberg D; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Priddy FH
    PLoS One; 2012; 7(4):e33103. PubMed ID: 22511916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
    Kibengo FM; Ruzagira E; Katende D; Bwanika AN; Bahemuka U; Haberer JE; Bangsberg DR; Barin B; Rooney JF; Mark D; Chetty P; Fast P; Kamali A; Priddy FH
    PLoS One; 2013; 8(9):e74314. PubMed ID: 24086333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactions and Receptivity to Framing HIV Prevention Message Concepts About Pre-Exposure Prophylaxis for Black and Latino Men Who Have Sex with Men in Three Urban US Cities.
    Mimiaga MJ; Closson EF; Battle S; Herbst JH; Denson D; Pitts N; Holman J; Landers S; Mansergh G
    AIDS Patient Care STDS; 2016 Oct; 30(10):484-489. PubMed ID: 27749110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
    Marcus JL; Glidden DV; Mayer KH; Liu AY; Buchbinder SP; Amico KR; McMahan V; Kallas EG; Montoya-Herrera O; Pilotto J; Grant RM
    PLoS One; 2013; 8(12):e81997. PubMed ID: 24367497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
    Paltiel AD; Freedberg KA; Scott CA; Schackman BR; Losina E; Wang B; Seage GR; Sloan CE; Sax PE; Walensky RP
    Clin Infect Dis; 2009 Mar; 48(6):806-15. PubMed ID: 19193111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
    Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL
    Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.